Dr. Reddys Labs (RDY) – Company Press Releases
-
Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
-
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
-
Dr. Reddy’s Q3 & 9M FY24 Financial Results
-
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
-
Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
-
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of
-
Dr. Reddy’s Q2 FY24 Financial Results
-
Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
-
Dr. Reddy’s Q1 FY24 Financial Results
-
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
-
Dr. Reddy’s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab
-
Dr. Reddy’s Q4 & FY23 Financial Results
-
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results
-
Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.
-
Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.
-
Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan
-
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results
-
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatmen
-
Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio
-
Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global’s Sustainability Yearbook for the 3rd year
-
Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market
-
Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe
-
Dr. Reddy’s Successfully Completes Phase 1 Study of DRL_TC, a Proposed Biosimilar of Tocilizumab
-
World Economic Forum Recognises Dr. Reddy’s Hyderabad Factory as Part of its Global Lighthouse Network
-
Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity
-
Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.
-
Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market
-
Dr. Reddy’s Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market
-
Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market
-
Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx
-
Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma
-
Eton Pharmaceuticals Announces Sale of Hospital Products
-
Eton Pharmaceuticals Announces Sale of Hospital Products
-
Dr. Reddy's Laboratories announces the launch of the generic version of Nexavar (sorafenib) Tablets, USP, 200 mg in the U.S. market
-
Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market
-
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market
-
Dr. Reddy's Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market
-
Dr. Reddy's Laboratories Announces the Launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market
-
Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany
-
Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany
-
Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT® (vasopressin injection, USP) Vials in the U.S. Market
-
Dr. Reddy's Laboratories Enters Into Definitive Agreement to Acquire German Medical Cannabis Firm Nimbus Health GmbH
-
Dr. Reddy’s Included in S&P Global’s Sustainability Yearbook for the 2nd Year and Bloomberg Gender-Equality Index for the 5th Year in a Row
-
Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market
-
Dr. Reddy's Laboratories Announces the Launch of Valsartan Tablets, USP in the U.S. Market
-
Prestige BioPharma and Dr. Reddy’s announce partnership to commercialize trastuzumab biosimilar in select countries in Latin America and Southeast Asia
-
Prestige BioPharma and Dr. Reddy’s announce partnership to commercialize trastuzumab biosimilar in select countries in Latin America and Southeast Asia
-
Dr. Reddy's Laboratories Announces the Launch of Ephedrine Sulfate Injection USP, 50 mg/mL, Single-Dose Vial in the U.S. Market
-
Dr. Reddy's Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)
-
Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market
Back to RDY Stock Lookup
